Among nine inconsistencies we classified three as major inconsistencies (type A): (1) The use of brain natriuretic peptide testing in patients when CHF is suspected (Table 5); (2) Angiotensin II receptor blockers (ARB) in addition to ACE inhibitors and beta-blockers (triple-therapy); and (3) ARB in combination with ACE inhibitors in beta-blocker-intolerant patients (substitution of beta-blockers). Here, ACE is linked to congestive heart failure.